ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Business

Sun Pharma's Shanghvi aims straight for the heart

 (placeholder image)
Dilip Shanghvi, co-founder and Managing Director of Sun Pharmaceutical Industries   © Reuters

MUMBAI -- India's Sun Pharmaceutical Industries has seen exceptional growth in the nation's massive generic-drug industry. The company has the highest total market value in an industry heavy with competition. To achieve this, co-founder and Managing Director Dilip Shanghvi has applied a sharply targeted takeover strategy and focuses production on pharmaceuticals for nerve and heart problems, which are in high demand across the globe.

 

    For the quarter to September, Sun Pharma turned in figures higher than planned, for both sales and profit, said Shanghvi. In September the company's share price reached record highs every day as the market anticipated healthy sales of carcinostatics, a drug category Sun Pharma dominates. Overseas sales account for about 70% of total sales. Sun Pharma has bought nearly 20 drug-related companies, helping it to establish a solid position to become a global enterprise.

     Sun Pharma has sufficient development capacity to introduce about 30 new products annually, a rate likely to rise this year. There is speculation that the company is considering takeovers of major U.S. and European companies. The coming year is seen as pivotal for the company's growth.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more